Cancer Treatment Reviews
Papers 2799
1 page of 280 pages (2,799 results)
Abstract Despite advances in translating conventional research into multi-modal treatment for colorectal cancer (CRC), therapeutic resistance and relapse remain unresolved in advanced resectable and, particularly, non-resectable disease. Genome and transcriptome sequencing and editing technologies, coupled with interaction mapping and machine learning, are transforming biomedical research, representing the most rational hope to overcome unmet research and clinical challenges. Rapid progress in b...
1 CitationsSource
#1Emilie Le Rhun (UZH: University of Zurich)H-Index: 1
#2Matthias Preusser (Medical University of Vienna)H-Index: 46
Last.Michael Weller (UZH: University of Zurich)H-Index: 110
view all 8 authors...
Abstract Glioblastomas are intrinsic brain tumors thought to originate from neuroglial stem or progenitor cells. More than 90% of glioblastomas are isocitrate dehydrogenase (IDH)-wildtype tumors. Incidence increases with age, males are more often affected. Beyond rare instances of genetic predisposition and irradiation exposure, there are no known glioblastoma risk factors. Surgery as safely feasible followed by involved-field radiotherapy plus concomitant and maintenance temozolomide chemothera...
#1Federica TomaoH-Index: 20
#2Erlisa BardhiH-Index: 4
view all 10 authors...
#1Gerben Lassche (Radboud University Nijmegen)H-Index: 1
#2Wim van Boxtel (Radboud University Nijmegen)H-Index: 2
Last.C.M.L. van Herpen (Radboud University Nijmegen)H-Index: 25
view all 5 authors...
Abstract Salivary gland cancer (SGC) is a rare malignancy consisting of 22 subtypes with different genetic, histological and clinical characteristics. This rarity and heterogeneity makes systemic treatment of recurrent or metastatic (R/M) disease challenging. Use of chemotherapy is scarcely studied and chemotherapy at best has moderate effects. New therapeutic strategies are therefore warranted, but advances made in SGC are lagging behind on advances made in more common cancers. By unraveling tu...
Last.Nicola Fazio (IEO: European Institute of Oncology)H-Index: 31
view all 8 authors...
Abstract Background Pancreatic ductal adenocarcinoma (PDAC) is one of the most lethal cancers worldwide. Recent studies have shown that 4-20% of patients with PDAC have a germline BReast CAncer (gBRCA) genes 1 and 2 mutation (m). Because homologous recombination is impaired in patients with gBRCAm, some reports suggested that these patients may be more sensitive to platinum compounds. Therefore, this systematic review and meta-analysis focused on benefit of patients with gBRCAm receiving a plati...
#1Daniel H. Schanne (UZH: University of Zurich)H-Index: 1
#2Jana Heitmann (UZH: University of Zurich)H-Index: 1
Last.Nicolaus Andratschke (UZH: University of Zurich)H-Index: 23
view all 4 authors...
Abstract Background The concept of oligometastatic disease (OMD) has expanded the scope of potentially curative therapy for metastatic NSCLC. However, large uncertainties remain regarding its definition and optimal management strategies. We therefore conducted a systematic review to investigate the value of various multimodality treatment concepts. Methods We searched the available literature in Pubmed, Medline and EMBASE using the terms “oligomet*”, “synchron*”, “oligorec*”, “metachr*” “NSCLC”,...
1 CitationsSource
#1Andrew Y. Li (University of Maryland Medical Center)
#2Michael G. McCusker (University of Maryland Medical Center)
Last.Christian Rolfo (University of Maryland Medical Center)
view all 9 authors...
Abstract The RET proto-oncogene has been well-studied. RET is involved in many different physiological and developmental functions. When altered, RET mutations influence disease in a variety of organ systems from Hirschsprung’s disease and multiple endocrine neoplasia 2 (MEN2) to papillary thyroid carcinoma (PTC) and non-small cell lung cancer (NSCLC). Changes in RET expression have been discovered in 30-70% of invasive breast cancers and 50-60% of pancreatic ductal adenocarcinomas in addition t...
#1Tong Lian (Tianjin Medical University)
#2Changying Li (Tianjin Medical University)
Last.Haitao Wang (Tianjin Medical University)
view all 3 authors...
Abstract The aberrant activation of RAS-derived mitogen-activated protein kinase (MAPK) signaling pathway plays a prominent role in tumorigenesis of an array of malignancies. The reasons are usually the upstream activated mutations including mitogen-activated protein kinase kinase 1/2 (MEK1/2). As oncogenic mutations, MEK1 mutations have been observed in a variety of malignancies including melanoma, histiocytic neoplasms, colorectal cancer and lung cancer. Presently, the use of trametinib, a hig...
#1Clare Kane (Mount Vernon Hospital)
#2Rob Glynne-Jones (Mount Vernon Hospital)H-Index: 48
Abstract The management of patients with “locally advanced rectal cancer” (LARC) is evolving from the original aim of reducing local recurrence. Current practice recognises the importance of surgical technique, high-quality preoperative imaging, and integration of neoadjuvant systemic chemotherapy. Contemporary protocols focus on improving survival and avoiding radical surgery with organ preservation strategies. Both short course preoperative radiotherapy (SCPRT) with immediate surgery and long-...
#1Hiroyuki Arai (SC: University of Southern California)
#2Francesca Battaglin (SC: University of Southern California)H-Index: 7
Last.H-J Lenz (SC: University of Southern California)H-Index: 79
view all 7 authors...
Abstract Regorafenib is a multi-targeting kinase inhibitor approved for the treatment of metastatic colorectal cancer patients in refractory to standard chemotherapy. Similarly to sorafenib, this agent was originally developed as a RAF1 inhibitor. However, the kinase inhibitory profile is distinct from sorafenib. A broad-spectrum of kinase inhibition induces wide-range drug sensitivity, irrespective of mutation status of major oncogenes. This agent’s main therapeutic effects are anti-angiogenesi...
Top fields of study